Payment overview · 2025
General Payments
$597.48
30 reported records · 9 companies
Healthcare provider profile · identity verified
Solomon Owusu, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JERSEY CITY, NJ · NPI 1487723243
Verified facts
What the public records show
CMS Open Payments records show Solomon Owusu, MD received $597.48 in general payments during 2025 across 30 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $210.54 | 35.2% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.24 | 23.8% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $82.93 | 13.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.71 | 7.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.43 | 6.4% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.97 | 4.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.27 | 3.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.87 | 2.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.52 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $597.48 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $122.55 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $122.55 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $102.25 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $82.93 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.43 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $35.17 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $27.97 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 56 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 114 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 13 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
29 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
114 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
56 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1100 | 244 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 780 | 157 |
| Pantoprazole Sodium | Pantoprazole Sodium | 532 | 145 |
| Metformin Hcl | Metformin Hcl | 439 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 423 | 105 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 421 | 123 |
| Hydralazine Hcl | Hydralazine Hcl | 380 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 373 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 330 | 63 |
| Pravastatin Sodium | Pravastatin Sodium | 316 | 66 |
| Carvedilol | Carvedilol | 231 | 45 |
| Gabapentin | Gabapentin | 217 | 57 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 202 | 121 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 50 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 168 | 44 |
| Januvia | Sitagliptin Phosphate | 152 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 33 |
| Simvastatin | Simvastatin | 124 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 114 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 106 | 78 |
| Ibuprofen | Ibuprofen | 106 | 40 |
| Montelukast Sodium | Montelukast Sodium | 106 | 18 |
| Omeprazole | Omeprazole | 106 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 105 | 22 |
| Glipizide Er | Glipizide | 102 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 101 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 21 |
| Ozempic | Semaglutide | 94 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 94 | 30 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 93 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 87 | 56 |
| Prednisone | Prednisone | 85 | 46 |
| Clobetasol Propionate | Clobetasol Propionate | 79 | 23 |
| Farxiga | Dapagliflozin Propanediol | 74 | 13 |
| Lactulose | Lactulose | 73 | 30 |
| Alprazolam | Alprazolam | 71 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 18 |
| Glimepiride | Glimepiride | 67 | 15 |
| Alendronate Sodium | Alendronate Sodium | 64 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | suppressed |
| Azithromycin | Azithromycin | 62 | 45 |
| Mometasone Furoate | Mometasone Furoate | 62 | 14 |
| Ammonium Lactate | Ammonium Lactate | 61 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 11 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 61 | 21 |
| Jardiance | Empagliflozin | 59 | 15 |
| Alcohol Pads | Alcohol Antiseptic Pads | 58 | 27 |
| Furosemide | Furosemide | 57 | suppressed |
| Losartan Potassium | Losartan Potassium | 57 | 16 |
| Lovastatin | Lovastatin | 56 | 13 |
| Rybelsus | Semaglutide | 56 | 18 |
| Mupirocin | Mupirocin | 55 | 25 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 13 |
| Allopurinol | Allopurinol | 52 | 13 |
| Metformin Hcl Er | Metformin Hcl | 51 | 18 |
| Entresto | Sacubitril/Valsartan | 50 | suppressed |
| Eliquis | Apixaban | 49 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Ofloxacin | Ofloxacin | 38 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 16 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 35 | 13 |
| Levofloxacin | Levofloxacin | 33 | 29 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Lidocaine | Lidocaine | 31 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 29 | 27 |
| Dilantin | Phenytoin Sodium Extended | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | 15 |
| Finasteride | Finasteride | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Fluconazole | Fluconazole | 21 | 11 |
| Naproxen | Naproxen | 21 | suppressed |
| Terconazole | Terconazole | 20 | 11 |
| Amoxicillin | Amoxicillin | 19 | 11 |
| Atovaquone-Proguanil Hcl | Atovaquone/Proguanil Hcl | 19 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | 12 |
| Methimazole | Methimazole | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | 14 |
| Pregabalin | Pregabalin | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Enulose | Lactulose | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Imiquimod | Imiquimod | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Mefloquine Hcl | Mefloquine Hcl | 13 | 12 |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Unifine Ultra Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 11 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $597.48 · 30 records | AstraZeneca Pharmaceuticals LP | BREZTRI, Dexcom G6 Transmitter, GVOKE HYPOPEN, JARDIANCE, Kerendia, MOUNJARO, Ohtuvayre, Ozempic, Rybelsus, TRELEGY ELLIPTA, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error